By SPC News Staff
The FDA expanded the indication of glecaprevir-pibrentasvir (Mavyret, AbbVie), allowing an eight-week treatment course for adults and certain children with hepatitis C virus (HCV).
The new course will be indicated for treatment-naive children aged 12 years and older or weighing at least 99 pounds with chronic HCV genotype 1, 2, 3, 4, 5 or 6 infection and compensated cirrhosis.